Background: Rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) chemotherapy remains the standard of first-line
treatment for diffuse large B-cell lymphoma (DLBCL). However, up to 40% of
DLBCL is characterized by relapse and refractory after treatment.
Preliminary study reported Hypoxia-inducible factor-1? (HIF-1?)
overexpression in 88.5% of DLBCL tumors in the Dr. Kariadi Hospital.
Moreover, the role of hypoxia and HIF-1? has previously never been explored
in DLBCL. Objectives: To evaluate the effect of hypoxia modulation to
increased chemotherapeutic response in DLBCL. Methods: Single blind
randomized control study was performed, with pre-test and post-test control
group design. Research sampling consisted of DLBCL patients who were treated
in the Dr. Kariadi Hospital. The inclusion criteria include newly diagnosed
DLBCL with HIF-1? overexpression and randomized to receive hypoxia
modulation consisting of carbogen inhalation and nicotinamide
administration, before R-CHOP chemotherapy. The tissue biopsy,
histopathology and immunohistochemical studies were done and assigned to the
intervention and control group. Chemotherapeutic responses were evaluated
after 10-14 days following the first cycle of R-CHOP chemotherapy. Results:
Out of twenty-six DLBCL participants with HIF-1? overexpression, there were
20 participants who completed the research protocol: 10 participants each in
the intervention and control group. Demographic, clinicopathological,
laboratory and disease characteristics were not statistically different
between the two research groups (p>0.05). Baseline tumor volume to be
evaluated was also considered equal (172.3 cm3 vs. 152.8 cm3, p=0.597).
Following the carbogen inhalation and nicotinamide administration, serum
HIF-1? and lactate reduction can be observed. There was also a significant
tumor volume shrinkage in both the intervention and control (mean -85.7 cm3
vs. -118.27 cm3) group, though the reduction was not statistically different
(Delta 58.85% vs. 65.63%, p=0.474). Conclusion: The addition of hypoxia
modulation to R-CHOP chemotherapy for DLBCL has showed beneficial effects on
both serum HIF-1a and lactate concentration. However, the benefits did not
correlate to increase a better tumor response compared to the control group.